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Abstract
Background: Hypertension is a global health concern for which novel treatment strategies are necessary. The aim
of this study is to evaluate the efficacy of resveratrol (trans-3, 5, 4′-trihydroxystilbene, a polyphenol present in
grapes) in controlling blood pressure in participants diagnosed with prehypertension and stage 1 hypertension.
Methods/design: In a randomized, crossover, double-blinded, placebo-controlled study, 50 participants with
prehypertension (diastolic blood pressure and systolic blood pressure, 80–89 mmHg and 120–139 mmHg, respectively)
and 50 participants with stage 1 hypertension (diastolic and systolic, 90–99 mmHg and 140–159 mmHg, respectively)
will be assigned to receive resveratrol (99 % pure, from Biotivia Longevity Bioceuticals LLC Company, USA, in 500 mg
capsules, twice daily for 4 weeks, orally) or placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks) in
a 2 × 2 crossover design (4 weeks treatment—4 weeks washout—4 weeks treatment). The blood pressure of each
participant will be recorded (a mean of two times within a 15-minute interval) every week during the study. The
participants in the prehypertensive group will not receive any medication, while those in the stage 1 hypertensive
group will continue to receive their routine medications during the study. Blood samples will be taken from all groups
and examined for various biochemical parameters.
Discussion: This trial will help to establish whether resveratrol is an effective antihypertensive agent in prehypertensive
and stage 1-hypertensive patients. The trial outcome will provide novel insight into the clinical efficacy of resveratrol
and provide valuable information for conducting future clinical studies with resveratrol.
Trial registration: Iranian Registry of Clinical Trials, IRCT201407078129N7. Registered on 15 August 2014.
Keywords: Resveratrol, Hypertension, Blood pressure, Polyphenol
Background
Worldwide, one in three adults is afflicted with elevated
blood pressure (BP) or hypertension; in comparison, dia-
betes affects one in ten adults [1]. High BP is one of the
most common risk factors for cardiovascular disease, af-
fecting approximately 40 % of the adult population
worldwide [2]. Currently, it accounts for 45 % and 51 %
of deaths resulting from coronary artery disease and
stroke, respectively. In addition, its prevalence is pro-
jected to reach as high as 1.5 billion by 2025 [2]. Ele-
vated BP results from varying factors such as genetics,
diet, lifestyle, and combinations thereof [3]. Hyperten-
sion may also further increase morbidity and mortality
due to other diseases in the presence of other risk factors.
Strategies for the prevention and management of hyper-
tension and associated adverse consequences are based on
lifestyle modification as well as pharmacological interven-
tions [3]. Notably, clinical trial evidence showed that a
large number of hypertensive participants (20–30 %) are
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resistant to the maximum tolerated dose of antihyperten-
sive drugs administered in various combinations, and
thus, managing hypertension remains an enormous chal-
lenge [4]. Accordingly, more effective alternative treat-
ment options that can clinically resolve this debilitating
condition should be developed to improve patient out-
comes and reduce the public health burden.
Wide-ranging dietary modifications and interventions
that include functional foods and nutraceuticals have been
shown to have promising antihypertensive effects in the
preclinical and clinical studies [3, 5–7]. The combination
of lifestyle, pharmacological, and other alternative ap-
proaches may prove beneficial in individuals affected by
hypertension and may also reduce the risk of the previ-
ously mentioned diseases.
In the past decade, considerable interest has developed
for using the plant polyphenol resveratrol to combat
hypertension and other forms of cardiovascular and
metabolic diseases. Resveratrol has been reported to
possess a dose-dependent antihypertensive effect in vari-
ous animal models of systemic hypertension such as the
spontaneously hypertensive rats (SHR) model, the angio-
tensin (Ang) II-infused mouse model, the two-kidney
one-clip hypertensive rat, and in partially nephrecto-
mized rats [8]. Moreover, resveratrol at a low dose
(2.5 mg/kg body weight/day) has been shown to enhance
the effect of other antihypertensive medication in the
SHR [9]. Additionally, resveratrol protects against and/
or reverses pulmonary hypertension in rat [10, 11]. Res-
veratrol is also effective in preventing high-fat-induced
and high-sucrose-induced arterial stiffness in nonhuman
primates [12]. Resveratrol-mediated reduction in hyper-
tension has been attributed to various mechanisms, in-
cluding improvement in oxidative stress, inflammation,
endothelial dysfunction, and vasodilation [8]. However,
clinical data from well-designed trials, which can be
translated to humans as a treatment option, are scarce.
Notably, resveratrol has been reported to lower BP in
diabetic patients [6, 13, 14]; however, no study to date
has specifically examined its potential in lowering BP in
persons diagnosed with hypertension.
We hypothesize that resveratrol administration (1 g/day
for 4 weeks) alone will reduce the BP or will complement
the standard antihypertensive medication in hypertensive
patients. For example, resveratrol may also have an incre-
mental effect in lowering high BP when taken along with
the standard antihypertensive medication. This would help
to reduce the dosage of antihypertensive medications
that have side effects. To test our hypothesis, a cross-
over, randomized, double-blinded, placebo-controlled
clinical trial involving 50 participants with prehyper-
tension and 50 participants with stage 1 hypertension
was designed. Blood pressure and biochemical param-
eters will be analyzed to test the antihypertensive
efficacy and mechanisms of action of resveratrol in
the study subjects.
Methods/design
Design overview and ethics approval
This study is a crossover, randomized, double-blinded,
placebo-controlled, single-center trial with an alloca-
tion ratio of 1:1 (Fig. 1). The participants, physician
(Daryoush Iranpour), principal investigator and physician
(Ali Movahed), and statistical consultant (Afshin Ostovar)
will be blinded to the allocation status. The records of
allocations will be kept confidential by methodology con-
sultant and will be disclosed only after blinded statistical
analyses or by request from Data and Safety Advisory
Board. This trial is an investigator-initiated study spon-
sored by the Persian Gulf Tropical Medicine Research
Center affiliated to Bushehr University of Medical Sciences,
Bushehr, Iran (Grant number: 3172, 93/4/17). The
study is approved by the regional research ethics
committee of BPUMS, Bushehr University of Medical
Sciences, approval NO: B-93-16- 4. The trial was regis-
tered with the Iranian Registry of Clinical Trials (IRCT)
(NO: IRCT201407078129N7) on 15 August 2014.
Study settings, population, and recruitment
The study will be conducted at the School of Medicine
of Bushehr University of Medical Sciences, Bushehr,
Iran. Prehypertensive (the mean of two measurements in
a 15-minute interval; diastolic and systolic BP, 80–89 mmHg
and 120–139 mmHg, respectively) and stage-1 hypertensive
(the mean of two measurements in a 15-minute interval;
diastolic and systolic BP, 90–99 mmHg and 140–
159 mmHg, respectively) males or females, aged between
20 and 60 years will be enrolled for the trial. The patients
for this study will be recruited through doctor referral at
the clinic and randomized to the treatment arm after the
initial screening and with their voluntary consent.
General objective
The objective of this trial is to determine whether res-
veratrol (99 % pure) treatment for 4 weeks will lower BP
in prehypertensive and stage 1-hypertensive patients.
Specific objectives
Primary objectives
The primary objectives of this trial are to determine the
BP-lowering effects of resveratrol on systolic, diastolic,
and mean arterial BP in participants diagnosed with pre-
hypertension and stage 1 hypertension.
Secondary objectives
The secondary objectives are as follows:
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 To determine if treatment with resveratrol lowers
levels of renin, angiotensin II, endothelin,
norepinephrine, tumor necrosis factor-α (TNF-α),
and oxidative stress markers and increases the
level of nitric oxide in prehypertensive and stage
1-hypertensive patients.
 To determine the effects of resveratrol on
hematologic indices in participants with
prehypertension and stage 1 hypertension.
 To determine the effects of resveratrol on lipid
profile in these patients.
 To determine the effects of resveratrol on liver
function markers in patients with prehypertension
and stage 1 hypertension.
 To determine the effects of resveratrol on renal
function markers in patients with prehypertension
and stage 1 hypertension.
Specific procedures
Serum renin, angiotensin II, endothelin, norepinephrine,
and TNF-α will be measured by ELISA kits (Thermo
Scientific, IL, USA). Nitric oxide (NO), malondialdehyde
and urinary isoprostanes will be measured by ELISA Kits,
spectrophotometry, gas chromatography/mass spectrom-
etry, respectively [15]. Hematocrit (HCT) and platelet
(PLT) will be estimated using a hematology cell counter
(Sysmex Analyzer). Prothrombin time (PT) and partial
thromboplastin time (PTT) will be measured using a
blood coagulameter. Analyses for biochemical parameters,
including fasting blood glucose (FBG), will be carried out
at the Persian Gulf Tropical Medicine Research Center
affiliated to Bushehr University of Medical Sciences
(BPUMS), Bushehr, Iran, using a Selectra 2 autoanalyzer
(Vital Scientific, Spankeren, Netherlands) [16]. Serum
total cholesterol and high-density lipoprotein cholesterol
(HDL) will be estimated using cholesterol oxidase phenol
amino antipyrine enzymatic method and triglyceride (TG)
using the glycerol-3-phosphate oxidase phenol amino an-
tipyrine enzymatic method [16]. Serum low-density lipo-
protein (LDL) cholesterol will be calculated using the
Friedewald formula [17]. Creatinine and blood urea nitro-
gen (BUN) levels will be estimated using enzymatic
method. In order to measure liver function in the patients,
alkaline phosphatase (ALP), gamma-glutamyl transferase
(GGT), bilirubin and albumin will be measured by enzyme
kinetic methods on a Selectra 2 autoanalyzer (Vital Scien-
tific, Spankeren, Netherlands [16]).
Eligibility criteria
Inclusion criteria are as follows:
 Prehypertensive (mean of two measurements in
a 15-minute interval; diastolic and systolic BP,
80–89 mmHg and 120–139 mmHg, respectively)
 Stage 1 hypertensive (mean of two measurements
in a 15 minute interval; diastolic and systolic BP,
90–99 mmHg and 140–159 mmHg, respectively)
 Male or female
 Age between 20 and 60 years
 Ability to provide informed consent
 Exclusion criteria are as follows:
 Approved or doubtful secondary hypertension
Fig. 1 Trial design
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 History of chronic or acute kidney disease
 History of heart failure
 History of chronic or acute liver diseases
 History of diabetes mellitus
 History of prior cardiovascular events (acute
myocardial infarction, cardiovascular diseases,
percutaneous coronary angioplasty or coronary
artery bypass graft)
 Pregnancy or breast feeding
 Blood arterial pressure > 180/110
 History of bowel disease of any etiology that may
affect absorption/or distribution of any drug
administered orally
 History of electrolyte imbalance during 3 months
prior to the enrolment
 History of alcohol abuse 4 weeks prior to the
enrolment
 Requiring a major surgical procedure (abdominal,
thoracic, neurovascular, urological, or gynecological)
during the course of the study
 Consumption of steroid hormones or nonsteroidal
anti-inflammatory drugs 1 month prior to the
enrolment
 History of hormonal changes (thyroid
and adrenal)
 Receiving lipid-lowering drugs
 History of bleeding disorders
 Receiving blood thinners
 Regular intake of omega-3 fatty acid, vitamins, and
mineral supplements
 Intention of having high intake of table salt or salty
foods
Informed consent
The patients will be informed about the trial by their
doctor during clinic visit. Interested individuals will
contact the study coordinator by telephone/
email[JMS1] . Interested individuals will be invited to
attend a first study visit by the concerned clinicians
on a specified day, when a pre-screening will be con-
ducted to exclude participants based on the inclusion/
exclusion criteria[K2] . If participants show up with
abnormal values for laboratory tests during pre-
screening, the tests will be repeated. If tests show
similar results (abnormal values) the participants will
be excluded from the study. If the criteria are met,
study coordinator will go through the consent form
designed in local language (Persian). Finally, clinical
trial details will be outlined and the participants will
be given an opportunity to ask any questions/con-
cerns. If they consent to the study, enrollment will be
completed. Participants will be enrolled only with
their voluntary informed consent (Appendix 1).
Randomization and intervention
After the enrolment of the patient is completed,
randomization will be done to allocate them to placebo or
resveratrol arms. A stratified complete block randomization
method will be used in this trial. Blocks of four will be used
for this purpose. The randomization scheme will be gener-
ated using random number formulae in Microsoft Excel.
Patients with prehypertension or stage 1 hypertension will
be separately randomized to receive active drug (resvera-
trol) in 500 mg capsules, twice daily for 4 weeks (sequence
A), or placebo (500 mg neutral microcellulose capsules),
twice daily for 4 weeks (sequence B), in a 2 × 2 crossover
design. The drug or placebo will be taken by patients at 7
to 8 a.m. in the morning on an empty stomach and
at 8 to 9 p.m. with 200 cc water. The patients will be
asked to record their conditions after taking the cap-
sules in case any unusual effects are experienced. At
the end of the 4 weeks, another 4-week washout
period will follow, during which the patients in both
sequences will receive placebo. All the participants
will be followed up for an additional 1-month period
for assessing any possible aftereffects (Fig. 1).
The study will be double-blinded (the patients, those
who will be participating in the study and those who
analyze the results will be unaware of the state of the pa-
tient with regard to receiving the active drugs or pla-
cebo). For this purpose, participants will be blinded by
using a placebo that is identical to active drug in appear-
ance, but the content is neutral cellulose. To blind those
who conduct the study, the person who delivers or
checks the study drug will be different from those who
examine the patients, and all the drugs packages will be
identified by unique numbers. Finally, the randomization
table will be concealed from research staff by using
closed envelops.
Compliance will be quantified by counting the number
of capsules consumed during the interval between the two
visits and presented as percentages (number consumed/
number expected to be consumed) × 100). If compliance
is less than 60 %, we will consider this case as noncompli-
ant. Noncompliant patients will be included under the
intention-to-treat analysis. Besides, at the analysis stage,
we will compare intention-to-treat (if randomized, then
we will analyze) and per-protocol analyses (those who
have received the treatment compared to those who have
not) and interpret the results.
Outcome measures
The primary outcome in this study will be BP. Systolic
and diastolic BPs will be measured by using a mercury
sphygmomanometer twice on patient in a sitting pos-
ition after a 10-minute rest and with a 15-minute inter-
val. The measurement will be done every week during
the intervention period. The mean systolic and diastolic
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BP will be computed. Mean arterial pressure will be calcu-
lated as systolic blood BP plus two times the diastolic BP
divided by three [(SBP + 2 ×DBP) ÷ 3]. The secondary out-
come will include the biochemical analysis of plasma or
serum for various biochemical and hematological markers.
Table 1 provides a list of secondary outcome mea-
sures. Table 2 shows the flow chart of the study.
Sample size
The sample size for the study was calculated by using
PASS 11 power and sample size software. Based on the
software output, a two-sided t test will achieve approxi-
mately 80 % power when the total sample size of a 2 × 2
cross-over design is n = 44, the actual mean difference
for systolic BP (as primary outcome) is 10, the square
root of the within mean square error is 10, and the
significance level is 0.05. Enrollment of 44 patients
would provide an 80 % power to demonstrate a significant
difference between the study arms. We expect approxi-
mately 10 % loss to follow-up. To achieve the calculated
statistical power, we decided to recruit 50 patients in each
strata (prehypertension and stage 1 hypertension group),
equally allocated to sequences A or B. In total, 100 pa-
tients will participate in this trial. To minimize loss to
follow-up, we give the participants a visit card. The next
visit time is recorded on the card based on the study
protocol. In addition, we call the participants, the day be-
fore, to remind them of their visit time, and again on the
day after if they fail to attend their visit on time to re-
invite them to reschedule soon.
Adverse effects
No reports exist of serious adverse effects in any of the
previous human studies with the 1-g resveratrol treat-
ment, including a recent study from our group where we
used a similar dosage of resveratrol in diabetic partici-
pants [11]. Nevertheless, any adverse event during the
study will be recorded. If the adverse effect is serious
enough to require medical attention, it will be reported
as soon as possible, and the Data and Safety Monitoring
Board (DSMB) will make a decision on whether or not
blinding should be removed and whether the patient
should be excluded from the study. In the case of a fatal
or severe event requiring hospital admission, reporting
should occur on the same day to the principal investigator.
For any adverse effect in its early stages (before any link
with the intervention is established) necessary treatment
will be given. The DSMB will be responsible for studying
each case individually to verify a possible link to study
products. The principal investigator will be responsible for
Table 1 List of biochemical markers
Outcome Method of measurement
LFT (ALP, GGT, albumin, bilirubin) Autoanalyzer (spectrophotometry)
Lipid profile (total cholesterol,
HDL, LDL, TG)
Autoanalyzer (spectrophotometry)
RFT (serum creatinine, BUN) Autoanalyzer (spectrophotometry)
Biochemical assessments
(endothelin, TNF-α, NO, renin,
angiotensin II, norepinephrine,
malondialdehyde, urinary
isoprostanes)
ELISA kits, spectrophotometry, gas
chromatography/mass
spectrometry
Hematological markers (PLT, HCT,
PT, PTT)
Autoanalyzer assay kits
Fasting blood glucose Autoanalyzer (spectrophotometry)
LFT liver function test, ALP alkaline phosphatase, GGT gamma-glutamyl transferase,
RFT renal function test, HDL high-density lipoprotein, LDL low-density lipoprotein,
TG triglycerides, TNF-α tumor necrosis factor-alpha, NO nitric oxide, PLT platelet,
HCT hematocrit, PT prothrombin time, PTT partial thromboplastin time, BUN blood
urea nitrogen
Table 2 Flow chart of the study
1 2 3 4 5 6 Washout 7 8 9 10 11 12
Week Screening Baseline 1 2 3 4 (4 weeks) 8 9 10 11 12 16
In/exclusion criteria checking ×
Enrolment ×
Obtaining informed consent ×
Physical examination ×
Randomization × ×
Blood pressure × × × × × × × × × × × ×
LFT × × × × ×
RFT × × × × ×
Lipid profile measurement × × × ×
Blood markers measurement × × × ×
Hematological indices and FBG measurement × × × × ×
Compliance measurement × × × × × × × × ×
Adverse effect checking × × × × × × × × ×
LFT liver function test, RFT renal function test, FBG fasting blood glucose
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managing the adverse effects clinically. Necessary services
will be provided free of charge. If any unexpected serious
or fatal adverse effect occurred that is believed to be due
to the consumption of resveratrol, the trial will be termi-
nated. The decision will be made by the DSMB.
Data quality control and management
All staff members who will collect and handle the data are
well trained for managing clinical data. Adequate attention
will be given to collect accurate and valid data and set up
a regular monitoring scheme by qualified staff. Original
hard copies of patient records will be kept at the recruit-
ment center, a copy will be sent to the research deputy of
BPUMS, and the data will be available only to designated
researchers involved in the trial. All patient documents
that are sent or received will be stored after taking into
consideration safety and security issues.
Necessary schemes will be set up to control the quality
of drug delivery, storage and handling, clinical examina-
tions, and laboratory tests.
Physical examination
Anthropometric parameters and clinical characteristics of
the participants, including age, sex, height, weight, and
body mass index (BMI) will be measured. The participants
will also be asked to fill out a standard questionnaire form
(developed by the United States Department of Agricul-
ture) regarding their typical food intake, including the
amount of salt, alcohol, green tea, coffee, grapes, peanuts,
wine, berries, and lifestyle (exercise, smoking, sleeping
habits, and rest) [15, 18]. In addition, the amount of vita-
mins and other micronutrients supplemented to the diet
will be included. At baseline, the patients will be asked to
fast (10-hour to 12-hour overnight fast) for blood collec-
tion. The blood samples will be collected before the first
stage of the study, after the 1-month intervention, after
the 1-month washout, and at the end of the study. Then,
the serum will be separated and given a code number and
stored at −80 °C until analysis.
Statistical analysis
Data will be analyzed on an intention-to-treat basis, de-
fined as all randomized patients who received at least
one dose of study medication. Patients with no data re-
corded for a parameter will be excluded from the ana-
lysis of that particular parameter. The statistician will
remain blinded to the status of the patients with regard
to the intervention. Data will be analyzed stratified by
prehypertension or stage 1-hypertension groups.
Final analyses will be conducted after the trial is fin-
ished or a decision has been made to stop the trial by
scientific steering committee, which may occur after the
interim analysis if the members are satisfied with the
strength of the evidence.
Because of a relatively long washout period, we do not
expect a significant carryover effect. However, we will
check for a carryover effect by using a two-group inde-
pendent t test to compare the average effects of out-
comes for the two sequences. Treatment, sequence, and
period effects will be estimated by using an analysis of
variance model for all outcome variables. Baseline values
of outcome variables as well as potential confounding
factors will be controlled by using repeated measure
analysis of variance models. Appropriate post-hoc ana-
lysis using Bonferroni correction for multiple compari-
sons will be performed.
Data will be analyzed by using the pk crossover menu
of Stat/SE 11.0 statistical software.
Discussion
The increasing need for alternative strategies for con-
trolling hypertension can be addressed by identifying
promising nutraceutical candidates. In this regard,
resveratrol has demonstrated great potential in prevent-
ing and/or reversing cardiovascular diseases including
hypertension in preclinical studies. Recent meta-analyses
[15, 18] that reviewed successful clinical trials [11, 12]
concluded that resveratrol may be considered as an ad-
juvant therapeutic candidate for managing type 2 dia-
betes. In light of these promising clinical findings and
previously reported preclinical evidence, resveratrol ap-
pears to be a potential antihypertensive agent. The effi-
cacy of resveratrol has yet to be clinically investigated in
patients with hypertension. This trial will be the first
study to investigate the potential of therapeutic use of
resveratrol for the management of BP in patients diag-
nosed with prehypertension and type 1 hypertension.
The outcomes from this study will help to determine the ef-
ficacy of short-term resveratrol treatment in hypertensive
patients and bridge the gap with regards to the current pre-
clinical and clinical evidence. This study will also help in
collecting further information with regard to identifying a
therapeutically effective dose of resveratrol in controlling
cardiovascular disease risk factors. Importantly, if a positive
outcome is identified, it will provide us with an effective
therapeutic strategy to combat hypertension and would
pave the way for achieving enormous public health benefit.
Study limitations
This trial is designed as a pilot study to investigate the
efficacy of resveratrol as a blood-pressure-lowering agent
in a specific population. In addition, the trial has a small
sample size. Hypertension is a condition that requires
long-term medication. Because the trial duration is only
4 weeks, longer-term studies need to be conducted to
evaluate the efficacy of resveratrol as a sustained treat-
ment option. In this study, participants will receive daily
only a single, high dose of resveratrol, which will be
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taken twice throughout the study (a high dose that is
well tolerated). Further trials may be needed to ascertain
whether resveratrol can lower BP at a much lower daily
dose. Another limitation is that a pharmacokinetics
study will not be done in this trial to understand the ab-
sorption, distribution, metabolism, and excretion of res-
veratrol in hypertensive patients; pharmacokinetics may
have helped to draw a correlation between the plasma
bioavailability and the actual physiological effect. In this
trial, stage 1-hypertensive patients will be on standard ther-
apy for hypertension as well; therefore, it may not be pos-
sible to understand the standalone efficacy of resveratrol in
lowering BP in these patients. Extensive toxicological ana-
lysis will also not be conducted as part of this study.
Trial status
Recruitment is in progress.
Appendix 1
Informed consent
The informed consent process and form will consist of
the following points:
 The patients will be informed that they are
participating in a clinical trial that assesses
the effectiveness of oral resveratrol in prehypertension
and stage 1 hypertension. Previous studies have
shown that the drug does not have serious adverse
effects at levels prescribed in this study and has had
favorable effects on the manifestations of the disease.
 This clinical trial will be done on 50 patients with
prehypertension (diastolic BP and systolic BP,
80–89 mmHg and 120–139 mmHg, respectively)
and 50 patients with stage 1 hypertension (diastolic
and systolic, 90–99 mmHg and 140–159 mmHg,
respectively) in the School of Medicine of Bushehr
University of Medical Sciences in Iran.
 Participants do not have to make a prompt
decision, and they can consult anybody they
want before making their final decision.
 All the participants should enter and stay in the study
voluntarily, and with full knowledge of the situation.
Therefore, they can leave the study at any time, and
this will not affect their ordinary appointments with
their doctor and they will receive their treatment as
before.
 All participants will undergo a thorough
investigation including clinical examinations and
laboratory tests to find out whether or not they are
eligible to enter the study. Half of the participants
from both groups (25 patients each) in this study
will receive resveratrol capsules (500 mg twice a day)
generously supplied by Biotivia Longevity Bioceuticals
LLC Company, USA, in the first period. The second
half of the participants both groups (another 25
patients) will receive a capsule identical to resveratrol
but with no active ingredient (produced by Biotivia
Longevity Bioceuticals LLC Company, USA). After
the completion of the 4 weeks, the participants will
crossover to receive the active drug or placebo for
another 4 weeks.
 During the treatment, participants will be examined
regularly (every week) by a physician or cardiologist
and will be consulted routinely. The BP and adverse
effects of the treatment will be assessed in each
visit and will be continued for 1 month after the
treatment period is over.
 In the event of adverse effects in participants
during the study and up to 1 month after the
study ends, all expenses for the necessary
treatment and laboratory investigation will
be paid for by the chief investigator as a part of
the grant.
 All information gathered during this study will be
kept confidential and will only be used by authorized
staff for analysis. The results from this study will be
published in scientific journals for public use.
 Expenses endured by participants because of this
study, including travel expenses to come to the
clinic, will be reimbursed by the investigation team
during the study period.
 Points of contact will be provided for participating
subjects to address their general and scientific
enquiries. Furthermore, a contact point to receive
complaints will be introduced.
 Participants are not waiving any of their legal rights by
signing this consent form, or releasing the investigator
from their legal and professional responsibilities.
 We will also let participants know about any new
information that may affect their health, welfare, or
willingness to stay in this study.
 Participants are free to ask any questions they may
have about their treatment and their rights as a
research participant. If any questions come up during
or after the study or if they have a research-related
injury, they can contact the study coordinator.
 Participants are encouraged not to sign this consent
form unless they have had a chance to ask questions
and have received satisfactory answers to all of their
questions
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